C4 Therapeutics (CCCC) Net Margin (2019 - 2025)
C4 Therapeutics' Net Margin history spans 7 years, with the latest figure at 184.87% for Q4 2025.
- For Q4 2025, Net Margin rose 48295.0% year-over-year to 184.87%; the TTM value through Dec 2025 reached 291.74%, up 422.0%, while the annual FY2025 figure was 292.08%, 388.0% up from the prior year.
- Net Margin reached 184.87% in Q4 2025 per CCCC's latest filing, up from 286.43% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 77.99% in Q4 2021 to a low of 1348.42% in Q2 2023.
- Average Net Margin over 5 years is 499.78%, with a median of 327.03% recorded in 2021.
- Peak YoY movement for Net Margin: tumbled -122492bps in 2022, then soared 120086bps in 2024.
- A 5-year view of Net Margin shows it stood at 77.99% in 2021, then plummeted by -1571bps to 1302.91% in 2022, then rose by 18bps to 1065.84% in 2023, then surged by 37bps to 667.82% in 2024, then skyrocketed by 72bps to 184.87% in 2025.
- Per Business Quant, the three most recent readings for CCCC's Net Margin are 184.87% (Q4 2025), 286.43% (Q3 2025), and 402.6% (Q2 2025).